About the Company

Gemphire Therapeutics is a clinical stage biotechnology company focused on the development of compounds for the treatment of diseases that affect cardiovascular and metabolic systems. The Company’s lead drug candidate is Gemcabene, which is currently being developed for the treatment of various dyslipidemias. Gemphire has ongoing clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, and also plans to initiate a study in severe hypertriglyceridemia (SHTG) imminently. Primary endpoints for the dyslipidemia trials all focus on lipid lowering, and topline results from these studies are expected in 2017. Due to the mechanism of action of gemcabene, this asset also has potential to treat liver indications such as NASH, which Gemphire may pursue in the future.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research